Key Points
- CFO John Glenn sold 15,000 shares on Dec. 11 at an average price of $97.29 for a total of $1,459,350, cutting his stake by 67.08% to 7,362 shares (≈$716k).
- iRadimed declared a special cash dividend of $0.50 per share with record and ex-dividend dates on Dec. 17 and payment on Dec. 30.
- The company beat quarterly EPS estimates ($0.47 vs. $0.43), issued Q4 2025 guidance of $0.470–0.510 and FY2025 guidance of $1.840–1.880, and carries a consensus analyst rating of Moderate Buy with an average price target of $87.33.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CFO John Glenn sold 15,000 shares of the business's stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
iRadimed Price Performance
Shares of iRadimed stock opened at $96.23 on Friday. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $98.44. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of 58.32 and a beta of 1.06. The company has a 50-day moving average of $84.16 and a 200 day moving average of $71.46.
iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The business had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.
iRadimed Announces Dividend
The business also recently disclosed a special dividend, which will be paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed's dividend payout ratio (DPR) is 41.21%.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on IRMD. Lake Street Capital reiterated a "buy" rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of iRadimed in a research report on Wednesday. Zacks Research upgraded iRadimed to a "hold" rating in a research note on Tuesday, November 4th. Roth Capital set a $90.00 price target on iRadimed in a research note on Friday, October 31st. Finally, Wall Street Zen downgraded iRadimed from a "strong-buy" rating to a "buy" rating in a report on Sunday, October 26th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, iRadimed presently has a consensus rating of "Moderate Buy" and an average price target of $87.33.
View Our Latest Report on iRadimed
Institutional Investors Weigh In On iRadimed
Large investors have recently added to or reduced their stakes in the stock. CWM LLC raised its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 211 shares during the last quarter. Quarry LP bought a new stake in shares of iRadimed in the third quarter worth $40,000. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 495 shares during the last quarter. State of Alaska Department of Revenue bought a new position in iRadimed in the third quarter valued at about $47,000. Finally, Spire Wealth Management purchased a new position in iRadimed in the second quarter worth about $60,000. Institutional investors own 92.34% of the company's stock.
About iRadimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
